CD274 and neoplasm: The KEYNOTE-024 phase III assessed pembrolizumab compared with investigator choice platinum-based chemotherapy in patients with NSCLC, without targetable mutation and with PD-L1 immunohistochemical tumour expression of greater than or equal to 50% using the Dako platform (22C3 antibody) (30.2% of screened cases) [32].